Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma

Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC). However, SOR prolongs survival by less than 3 months and does not alter symptomatic progression. To improve outcomes, several phase I-II trials are currently examining SOR with radiation (RT) for...

Full description

Saved in:
Bibliographic Details
Main Authors: Wild, Aaron T., Gandhi, Nishant, Chettiar, Sivarajan T., Aziz, Khaled, Gajula, Rajendra P., Williams, Russell D., Kumar, Rachit, Taparra, Kekoa, Zeng, Jing, Cades, Jessica A., Velarde, Esteban, Menon, Siddharth, Geschwind, Jean F., Cosgrove, David, Pawlik, Timothy M., Maitra, Anirban, Wong, John, Hales, Russell K., Torbenson, Michael S., Herman, Joseph M., Tran, Phuoc T.
Format: Artigo
Language:Inglês
Published: Public Library of Science 2013
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675179/
https://ncbi.nlm.nih.gov/pubmed/23762417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0065726
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items